Gapping up
In reaction to earnings/guidance:
- MLKN +12.2%, BNTX +8.1%, LULU +7% (also authorizes $1 bln stock repurchase program), HLTH +6.7%, MU +3.9%, CALM +2.1%, PRGS +2.1%, VRNT +1.8%, SLGC +1%
Other news:
- ADGI +68.1% (announces ADG20 (adintrevimab) is the first monoclonal antibody to meet primary endpoints with statistical significance across pre- and post-exposure prophylaxis and treatment for COVID-19 and plans to seek US emergency use authorization)
- VIR +11.6% (to be added to S&P SmallCap 600)
- SUNL +7.6% (names new CFO)
- RMO +7.1% (announces shipment of first pedigree packs to key customer)
- AMLX +5% (ahead of FDA NDA meeting for AMX0035)
- CSTL +3% (granted Advanced Diagnostic Laboratory Test status by CMS)
- QTRX +3% (partners with Alzheimer's Foundation to accelerate development of multi-analyte plasma test for early detection of Alzheimer's disease)
- DOOO +2.9% (announces terms of $250000000 substantial issuer bid)
- NSC +2.6% (authorizes new $10 bln stock repurchase program)
- CALM +2.1% (announces that its Board of Directors has approved new capital projects to further expand the Company's cage-free egg production capabilities)
- REPL +2% (provides new clinical data broad program update and future development strategy for its tumor-directed oncolytic immunotherapies)
- TWI +1.7% (divests its Australian Wheel Business)
- CVAC +1.4% (CureVac and GlaxoSmithKline (GSK) to develop second-gen COVID-19 vaccine candidate CV2CoV)
Analyst comments:
- FRPT +3.4% (upgraded to Buy from Neutral at Goldman)